Ling v. Hhs

CourtCourt of Appeals for the Federal Circuit
DecidedDecember 6, 2023
Docket23-1072
StatusUnpublished

This text of Ling v. Hhs (Ling v. Hhs) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ling v. Hhs, (Fed. Cir. 2023).

Opinion

Case: 23-1072 Document: 32 Page: 1 Filed: 12/06/2023

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

BRUCE A. LING, JR., Petitioner-Appellant

v.

SECRETARY OF HEALTH AND HUMAN SERVICES, Respondent-Appellee ______________________

2023-1072 ______________________

Appeal from the United States Court of Federal Claims in No. 1:20-vv-00061-EHM, Judge Edward H. Meyers. ______________________

Decided: December 6, 2023 ______________________

BRUCE A. LING, JR., Tallahassee, FL, pro se.

EMILIE WILLIAMS, Torts Branch, Civil Division, United States Department of Justice, Washington, DC, for re- spondent-appellee. Also represented by BRIAN M. BOYNTON, C. SALVATORE D’ALESSIO, HEATHER LYNN PEARLMAN. ______________________

Before LOURIE, DYK, and TARANTO, Circuit Judges. Case: 23-1072 Document: 32 Page: 2 Filed: 12/06/2023

PER CURIAM.

Bruce A. Ling, Jr. once again seeks compensation un- der the National Vaccine Injury Compensation Program, 42 U.S.C. § 300aa-10 to -34 (“Vaccine Act”), based on his allegations that a seasonal influenza vaccination he re- ceived in November 2011 caused him to develop Guillain- Barré Syndrome (“GBS”). The special master denied his claim, finding that Ling did not present sufficient evidence to substantiate his allegation that he suffered from GBS. Ling v. Sec’y of Health & Hum. Servs., No. 20-61V, 2021 WL 3913935, at *4 (Fed. Cl. Spec. Mstr. Aug. 17, 2021) (“Decision”). The United States Court of Federal Claims (“Claims Court”) dismissed Ling’s untimely motion for review but concluded that, even if the motion had been timely, the special master’s decision was not arbitrary or capricious. Ling v. Sec’y of Health & Hum. Servs., No. 20- 61V (Fed. Cl. Mar. 3, 2022), R.A. 6–12. 1 Thereafter, Ling filed two motions for reconsideration, which the Claims Court denied. Ling then filed a petition for review in this court. For the following reasons, we dismiss Ling’s appeal. BACKGROUND Ling has filed three pro se petitions under the Vaccine Act, each alleging injuries from the same November 2011 flu vaccination. His first petition was denied on the merits after he could not substantiate his alleged, unspecified in- jury. Ling v. Sec’y of Health & Hum. Servs., No. 14-1017, 2017 WL 3814649, at *4 (Fed. Cl. July 21, 2017). His sec- ond petition was dismissed because he had a civil suit pending in the United States District Court for the North- ern District of Florida at the time his petition was filed. Ling v. Sec’y of Health & Hum. Servs., 145 Fed. Cl. 778,

1 “R.A.” refers to the appendix filed with Respond- ent-Appellee’s brief. Case: 23-1072 Document: 32 Page: 3 Filed: 12/06/2023

LING v. HHS 3

783–84 (2019); see Flowers v. Sec’y of Dep’t of Health & Hum. Servs., 49 F.3d 1558, 1561 (Fed. Cir. 1995) (holding that § 300aa-11(a)(5)(B) “prohibit[s] the filing of any Vac- cine Act petition in which the petitioner has a co-pending civil action, irrespective of the date of that co-pendency”). Ling now seeks compensation for a third time, alleging that a 2019 GBS diagnosis by his physician substantiates his claim for relief. R.A. 23, 31. On August 17, 2021, the special master denied Ling’s claim, finding that Ling had not produced “persuasive evi- dence” of a GBS diagnosis. Decision at *4. A copy of the decision was served on Ling via U.S. Mail. R.A. 8. On Sep- tember 1, 2021, the Claims Court published the special master’s decision on its website, and a copy of that pub- lished decision was again served on Ling via U.S. Mail. Id. at 3, 8. Judgment was entered against Ling on September 17, 2021. Id. at 3, 8; see 42 U.S.C. §§ 300aa-12(e)(1), (3) (“In the absence of a motion [for review of] the special master’s decision . . . the clerk of the [Claims Court] shall immedi- ately enter judgment in accordance with the special mas- ter’s decision.”); see also Vaccine Rule 11(a). On October 12, 2021, only after judgment had been en- tered, did Ling file a motion for review of the special mas- ter’s decision. R.A. 4, 8. He alleged, inter alia, that he never received the mailed copy of the special master’s Au- gust 17, 2021 decision, and that the delay prejudiced him in preparing his motion and violated his right to due pro- cess. See id. at 72–73, 77–80. As for the merits, he main- tained that the evidence he submitted was sufficient to support a GBS diagnosis. Id. at 74–77. On March 3, 2022, the Claims Court dismissed Ling’s motion, holding that it was untimely because, even if Ling had not received the mailed copy of the August 17, 2021 decision, he had received the copy of the published, Sep- tember 1, 2021 decision. Id. at 10. This meant that Ling had at least 19 days to move for review upon receiving a Case: 23-1072 Document: 32 Page: 4 Filed: 12/06/2023

copy of the decision, which did not rise to the level of a due process violation. Id.; see Hervey v. Sec’y of Health & Hum. Servs., 88 F.3d 1001, 1003 (Fed. Cir. 1996) (holding that a shortened period of 20 days to file a motion for review did not violate vaccine petitioner’s right to due process). Ac- cordingly, the Claims Court determined that it lacked ju- risdiction over Ling’s motion for review. R.A. 10 (citing Widdoss v. Sec’y of Dep’t of Health & Hum. Servs., 989 F.2d 1170, 1177 (Fed. Cir. 1993) (holding that the thirty-day deadline to file a motion for review under § 300aa-12(e)(1) is jurisdictional)). 2 Nevertheless, the Claims Court deter- mined that, even if it had jurisdiction, the special master’s decision was not arbitrary or capricious because there was no evidence that Ling in fact had GBS. R.A. 11. Thereafter, Ling filed two motions for reconsideration, which were denied on April 12, 2022, and June 27, 2022, respectively. Id. at 4. On August 15, 2022, Ling petitioned for review in this court. Id. at 5.

2 As the Claims Court observed, since Widdoss, the Supreme Court has emphasized “the distinction between jurisdictional prescriptions and nonjurisdictional claim- processing rules, which ‘seek to promote the orderly pro- gress of litigation by requiring that the parties take certain procedural steps at certain specified times.’” Fort Bend County v. Davis, 139 S. Ct. 1843, 1849 (2019) (citation omitted); see ECC Int’l Constructors, LLC v. Sec’y of Army, 79 F.4th 1364 (Fed. Cir. 2023). We have not resolved whether or not that recent guidance affects our holding in Widdoss. See Gaiter v. Sec’y of Health & Hum. Servs., 784 F. App’x 759, 762–63 (Fed. Cir. 2019). But we need not reach that issue here, where, as explained below, Ling’s pe- tition for review in this court was also untimely. Case: 23-1072 Document: 32 Page: 5 Filed: 12/06/2023

LING v. HHS 5

DISCUSSION Section 300aa-12(f) of the Vaccine Act states that the Secretary or any petitioner aggrieved by the findings or conclusions of the Claims Court on a petition for compen- sation may obtain review in this court “upon petition filed within 60 days of the date of judgment.” 42 U.S.C. § 300aa- 12(f); see 28 U.S.C. § 1295(a)(3) (granting this court juris- diction over “an appeal from a final decision” of the Claims Court).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Browder v. Director, Dept. of Corrections of Ill.
434 U.S. 257 (Supreme Court, 1978)
McNeil v. United States
508 U.S. 106 (Supreme Court, 1993)
Erickson v. Pardus
551 U.S. 89 (Supreme Court, 2007)
Santos-Zacaria v. Garland
598 U.S. 411 (Supreme Court, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
Ling v. Hhs, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ling-v-hhs-cafc-2023.